| Literature DB >> 29655456 |
Vita G Kesner1, Shin J Oh2, Mazen M Dimachkie3, Richard J Barohn3.
Abstract
Lambert-Eaton myasthenic syndrome is a paraneoplastic or primary autoimmune neuromuscular junction disorder characterized by proximal weakness, autonomic dysfunction and ariflexia. The characteristic symptoms are thought to be caused by antibodies generated against the P/Q-type voltage-gated calcium channels present on presynaptic nerve terminals and by diminished release of acetylcholine. More than half of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung carcinoma. Diagnosis is confirmed by serologic testing and electrophysiologic studies. 3,4-diaminopyridine is effective symptomatic treatment of LEMS.Entities:
Keywords: 3,4-Diaminopyridine; Lambert-Eaton myasthenic syndrome; Neuromuscular transmission disorder; P/Q-type voltage-gated calcium channels; Paraneoplastic syndrome
Mesh:
Year: 2018 PMID: 29655456 PMCID: PMC6690495 DOI: 10.1016/j.ncl.2018.01.008
Source DB: PubMed Journal: Neurol Clin ISSN: 0733-8619 Impact factor: 3.806